Analytics that Matter- How LC and MALS Drive Biosimilar Success

Why It Matters

By allowing analytics to supplant costly clinical trials, the guidance accelerates time‑to‑market and cuts development expenses, giving manufacturers a competitive edge in the fast‑growing biosimilar market.

Key Takeaways

• FDA draft encourages analytics over clinical efficacy studies
• LC and MALS provide detailed molecular characterization
• Orthogonal techniques become essential for biosimilar approval
• Waters offers integrated solutions for totality‑of‑evidence packages
• Reduced clinical trials lower development costs and timelines

Pulse Analysis

The biosimilar sector is at a pivotal juncture as regulators pivot toward data‑driven approval pathways. The October 2025 FDA draft guidance marks a departure from the traditional reliance on extensive comparative clinical trials, instead championing a "totality‑of‑evidence" framework anchored in high‑resolution analytical characterization. This shift reflects broader industry trends where precision measurement can uncover subtle structural and functional differences that clinical endpoints may miss, ultimately fostering greater confidence in biosimilarity assessments.

Liquid chromatography (LC) paired with multi‑angle light scattering (MALS) has emerged as a cornerstone of this analytical renaissance. LC separates complex protein mixtures, while MALS quantifies absolute molecular weight and size distributions in real time, delivering a detailed picture of aggregation, charge variants, and higher‑order structures. When combined with orthogonal methods such as capillary electrophoresis or mass spectrometry, these techniques provide a robust, reproducible data set that satisfies the FDA’s heightened expectations for comparability without the need for large‑scale efficacy studies.

For manufacturers, the operational impact is profound. Eliminating or trimming clinical efficacy studies can shave months off development timelines and reduce budgets by tens of millions of dollars per program. Companies like Waters are capitalizing on this regulatory evolution by offering integrated LC‑MALS platforms, software suites, and consulting services that streamline data generation and interpretation. As the market for biosimilars expands, firms that adopt these advanced analytics will likely secure faster approvals, lower costs, and stronger market positioning, reshaping the competitive landscape of biologics.